{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"45"}],"title":"Responder"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"83"}],"title":"Non-responder"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"128"}],"units":"Participants"}],"description":"A complete response is defined as complete disappearance of all target lesions. A partial response is ≥10% decrease tumor size at computed tomography (CT) or ≥15% decrease in tumor attenuation at computed tomography (CT) and no new lesions. The response rate is defined as complete response plus partial response.","groups":[{"description":"Patients with a PDGFRA D842V mutation, any line of treatment","id":"OG000","title":"Patients With a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy","id":"OG001","title":"2L Patients Without a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy","id":"OG002","title":"3L Patients Without a PDGFRA D842V Mutation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg","reportingStatus":"POSTED","timeFrame":"Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.","title":"Response Rate Determined by Central Radiology Assessment Per Choi Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}